• Erasca released a preliminary Phase 1 update for ERAS-0015 from the AURORAS-1 first-in-human trial.
• In 2L+ KRAS G12X pancreatic ductal adenocarcinoma, uORR reached 57% at 32 mg once daily (4/7) through May 25, 2026.
• Disease control rate was 100% at 32 mg (7/7) through May 25, 2026; 24 mg showed 25% uORR (2/8).
• In colorectal cancer, the ERAS-0015 16 mg once-daily combination with panitumumab showed no DLTs; 24 mg cohort enrolling as of July 6, 2026.
• Milestones target monotherapy expansion initiation in 2H26; combination dose-escalation data, including panitumumab, in 1H27.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Erasca Inc. published the original content used to generate this news brief on July 13, 2026, and is solely responsible for the information contained therein.